Del-1 gene therapy - Indevus Pharmaceuticals

Drug Profile

Del-1 gene therapy - Indevus Pharmaceuticals

Latest Information Update: 13 Jul 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indevus Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Cardiovascular disorders

Most Recent Events

  • 13 Jul 1999 Del-1 gene therapy - Progenitor is now called Del-1 gene therapy - Interneuron
  • 13 Jul 1999 Discontinued-Preclinical for Cancer in USA (Unknown route)
  • 13 Jul 1999 Discontinued-Preclinical for Cardiovascular disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top